Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717989 | 1.00 | HCAR2 (0.35) | HCAR2KDM4EALPLHSD17B10ALDH1A1 | |
| SCHEMBL28686135 | 0.80 | AURKA (0.40) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL22746962 | 0.80 | AURKA (0.40) | KDM4EHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29071888 | 0.79 | AURKA (0.40) | KDM4EHSD17B10ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL29071885 | 0.79 | AURKA (0.40) | KDM4EHSD17B10ALDH1A1KMT2A | |
| SCHEMBL23513289 | 0.77 | BRD4 (0.42) | ALDH1A1KMT2A | |
| SCHEMBL29838182 | 0.73 | HCAR2 (0.37) | HCAR2KDM4EALPLHSD17B10ALDH1A1 | |
| SCHEMBL16517228 | 0.72 | KDM4E (0.36) | HCAR2KDM4EALPLHSD17B10ALDH1A1 | |
| SCHEMBL29760453 | 0.71 | HCAR2 (0.42) | HCAR2KDM4EALPLHSD17B10ALDH1A1 | |
| SCHEMBL22718165 | 0.71 | HCAR2 (0.33) | HCAR2KDM4EALPLHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4255571-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-11 | — | — | EP | disclosed |
| CN-116744927-A | Fused heterocyclic derivatives and their use in the treatment of HBV infection | 杨森科学爱尔兰无限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116999-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116997-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | HCAR2 1432/4885KDM4E 3515/4885ALPL 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.